NCT03101722

Effects of Huperzine a on Presbycusis(Δ,kHz, DB,MMSE, AD)

Effects of Huperzine a on Presbycusis-related Subjective Tinnitus and Cognitive Impairment

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Zhijun Bao · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

To investigate the effects of huperzine A on tinnitus suppression, hearing and cognitive function protection in patients with presbycusis-related subjective tinnitus and cognitive impairment.

Detailed description

This study is a randomized, controlled trial. 60 eligible participants in total will be recruited. Participants in each group will be evenly and randomly assigned to the huperzine A subgroup and control subgroup using simple randomization method. Participants in the treatment subgroup will receive huperzine A (a dose of 0.2 mg/time, 2 times/day) with basic treatment and health education(BTHE), and those in the control subgroup will receive BTHE only. The primary outcome (auditory function) and secondary outcomes (tinnitus, cognitive symptom and quality of life) will be evaluated at baseline, 3-, 6-, 12-month follow-up.

Conditions

• Presbycusis
• Tinnitus
• Cognitive Impairment

Interventions

Type	Name	Description
DRUG	BTHE and Huperzine A	huperzine A intervention
OTHER	BETH	basic treatment and health education

Timeline

• Start date: 2017-05-15
• Primary completion: 2030-09-15
• Completion: 2030-09-15
• First posted: 2017-04-05
• Last updated: 2024-10-01

Locations

1 site across 1 country: China